{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:37:14Z","timestamp":1790825834767,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.abd.2020.05.006","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T08:56:10Z","timestamp":1602147370000},"page":"39-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"S1","title":["Consensus on the treatment of alopecia areata \u2013 Brazilian Society of Dermatology"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1561-414X","authenticated-orcid":false,"given":"Paulo M\u00fcller","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-7757","authenticated-orcid":false,"given":"Alessandra","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-3049","authenticated-orcid":false,"given":"Bruna","family":"Duque-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8807-2556","authenticated-orcid":false,"given":"Daniel Fernandes","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-8535","authenticated-orcid":false,"given":"Flavia","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1052-1777","authenticated-orcid":false,"given":"Leopoldo Duailibe Nogueira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-7102","authenticated-orcid":false,"given":"Lorena Dourado","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-522X","authenticated-orcid":false,"given":"Fabiane","family":"Mulinari-Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2020.05.006_bib0005","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009","volume":"134","author":"Mirzoyev","year":"2014","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1590\/abd1806-4841.20188802","article-title":"Profile of dermatological consultations in Brazil (2018)","volume":"93","author":"Sociedade Brasileira de Dermatologia","year":"2018","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40257-014-0086-4","article-title":"Alopecia areata: an evidence-based treatment update","volume":"15","author":"Hordinsky","year":"2014","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.23736\/S0392-0488.19.06458-7","article-title":"Italian Guidelines in diagnosis and treatment of alopecia areata","volume":"154","author":"Rossi","year":"2019","journal-title":"G Ital Dermatol Venereol."},{"key":"10.1016\/j.abd.2020.05.006_bib0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40257-017-0297-6","article-title":"Alopecia Areata of the Beard: a review of the literature","volume":"18","author":"Cervantes","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000066435","article-title":"Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse alopecia areata that has a favorable prognosis","volume":"205","author":"Sato-Kawamura","year":"2002","journal-title":"Dermatology."},{"key":"10.1016\/j.abd.2020.05.006_bib0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000254503","article-title":"A new classification of alopecia areata","volume":"131","author":"Ikeda","year":"1965","journal-title":"Dermatologica."},{"key":"10.1016\/j.abd.2020.05.006_bib0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: an Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0045","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/jdv.15994","article-title":"Alopecia totalis and universalis long-term outcomes: a review","volume":"34","author":"Burroway","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2020.05.006_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-5945-5-1","article-title":"Concepts of patients with alopecia areata about their disease","volume":"5","author":"Firooz","year":"2005","journal-title":"BMC Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0055","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.clindermatol.2018.08.011","article-title":"Psychosomatic aspects of alopecia areata","volume":"36","author":"Mulinari-Brenner","year":"2018","journal-title":"Clin Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0060","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1590\/S0365-05962012000300010","article-title":"Hair loss perception and symptoms of depression in female outpatients attending a general dermatology clinic","volume":"87","author":"Schmitt","year":"2012","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0065","first-page":"6063","article-title":"Severity of depression and anxiety in patients with Alopecia Areata in Bandar Abbas","volume":"7","author":"Baghestani","year":"2015","journal-title":"Iran. Dermatol Reports."},{"key":"10.1016\/j.abd.2020.05.006_bib0070","article-title":"Psychodermatology: knowledge, awareness, practicing patterns, and attitudes of dermatologists in Turkey","volume":"17","author":"Ocek","year":"2015","journal-title":"Prim Care Companion CNS Disord."},{"key":"10.1016\/j.abd.2020.05.006_bib0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaad.2005.09.025","article-title":"Hypnotherapeutic management of alopecia areata","volume":"55","author":"Willemsen","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1365-2133.2003.05535.x","article-title":"Guidelines for the management of alopecia areata","volume":"149","author":"MacDonald Hull","year":"2003","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/0974-7753.111223","article-title":"A study to evaluate the efficacy of various topical treatment modalities for alopecia areata","volume":"4","author":"Sardesai","year":"2012","journal-title":"Int J Trichol."},{"key":"10.1016\/j.abd.2020.05.006_bib0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/abd1806-4841.20187423","article-title":"Intralesional betamethasone as a therapeutic option for alopecia areata","volume":"93","author":"Melo","year":"2018","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2016.10.004","article-title":"Alopecia areata: what\u2019s new in epidemiology, pathogenesis, diagnosis, and therapeutic options?","volume":"86","author":"Dainichi","year":"2017","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.abd.2020.05.006_bib0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","article-title":"Alopecia areata update: part II. Treatment","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0974-7753.82123","article-title":"Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata","volume":"3","author":"Kuldeep","year":"2011","journal-title":"Int J Trichol."},{"key":"10.1016\/j.abd.2020.05.006_bib0110","first-page":"757","article-title":"Alopecia areata: part 2: treatment","volume":"61","author":"Spano","year":"2015","journal-title":"Can Fam Physician."},{"key":"10.1016\/j.abd.2020.05.006_bib0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12788\/j.sder.2015.0160","article-title":"Alopecia areata update","volume":"34","author":"Hordinsky","year":"2015","journal-title":"Semin Cutan Med Surg."},{"key":"10.1016\/j.abd.2020.05.006_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1346-8138.2011.01476.x","article-title":"Advances in the management of alopecia areata","volume":"39","author":"Ito","year":"2012","journal-title":"J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0125","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaad.2019.11.066","article-title":"Efficacy of different concentrations of intralesional triamcinolone acetonide for alopecia areata: a systematic review and meta-analysis","volume":"82","author":"Yee","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2015.04.049","article-title":"Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study","volume":"73","author":"Chu","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0135","first-page":"751","article-title":"Alopecia areata: part 1: pathogenesis, diagnosis, and prognosis","volume":"61","author":"Spano","year":"2015","journal-title":"Can Fam Physician."},{"key":"10.1016\/j.abd.2020.05.006_bib0140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1067\/mjd.2003.423","article-title":"Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis\/universalis","volume":"49","author":"Tosti","year":"2003","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40272-017-0239-z","article-title":"Alopecia Areata: an update on treatment options for children","volume":"19","author":"Peloquin","year":"2017","journal-title":"Paediatr Drugs."},{"key":"10.1016\/j.abd.2020.05.006_bib0150","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2230.2007.02367.x","article-title":"Lack of response of alopecia areata to pimecrolimus cream","volume":"32","author":"Rigopoulos","year":"2007","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0155","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2133.2004.05785.x","article-title":"Minoxidil: mechanisms of action on hair growth","volume":"150","author":"Messenger","year":"2004","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0160","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/187221312800166859","article-title":"Minoxidil use in dermatology, side effects and recent patents","volume":"6","author":"Rossi","year":"2012","journal-title":"Recent Pat Inflamm Allergy Drug Discov."},{"key":"10.1016\/j.abd.2020.05.006_bib0165","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.15545","article-title":"Minoxidil for patchy alopecia areata: systematic review and meta-analysis","volume":"33","author":"Freire","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2020.05.006_bib0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","article-title":"Alopecia areata: an appraisal of new treatment approaches and overview of current therapies","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0175","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1087-0024.2003.00812.x","article-title":"Old wine in new bottles: reviving old therapies for alopecia areata using rodent models","volume":"8","author":"Tang","year":"2003","journal-title":"J Investig Dermatol Symp Proc."},{"key":"10.1016\/j.abd.2020.05.006_bib0180","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjd.14040","article-title":"Diphenylcyclopropenone in patients with alopecia areata. A critically appraised topic","volume":"173","author":"Kuin","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/jidsymp.2015.28","article-title":"Clinical efficacy of Diphenylcyclopropenone in Alopecia Areata: retrospective data analysis of 50 patients","volume":"17","author":"Chiang","year":"2015","journal-title":"J Investig Dermatol Symp Proc."},{"key":"10.1016\/j.abd.2020.05.006_bib0190","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/pde.13703","article-title":"Treatment of pediatric alopecia areata with anthralin: a retrospective study of 37 patients","volume":"35","author":"Wu","year":"2018","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaad.2004.10.873","article-title":"Placebo-controlled oral pulse prednisolone therapy in alopecia areata","volume":"52","author":"Kar","year":"2005","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0200","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000092287","article-title":"A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata","volume":"212","author":"Kurosawa","year":"2006","journal-title":"Dermatology."},{"key":"10.1016\/j.abd.2020.05.006_bib0205","first-page":"284","article-title":"Efficacy and safety of oral mega pulse methylprednisolone for severe therapy resistant Alopecia areata","volume":"33","author":"Bin Saif","year":"2012","journal-title":"Saudi Med J."},{"key":"10.1016\/j.abd.2020.05.006_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-016-0111-8","article-title":"Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids","volume":"18","author":"Parente","year":"2017","journal-title":"BMC Pharmacol Toxicol."},{"key":"10.1016\/j.abd.2020.05.006_bib0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000471771","article-title":"Trichoscopy of steroid-induced atrophy","volume":"3","author":"Pirmez","year":"2017","journal-title":"Skin Appendage Disord."},{"key":"10.1016\/j.abd.2020.05.006_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.01.062","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaad.2016.02.1239","article-title":"Prevention and management of glucocorticoidinduced side effects: a comprehensive review: Gastrointestinal and endocrinologic side effects","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0230","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2016.02.1240","article-title":"Prevention and management of glucocorticoidinduced side effects: a comprehensive review: infectious complications and vaccination recommendations","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0235","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaad.2016.02.1241","article-title":"Prevention and management of glucocorticoidinduced side effects: a comprehensive review: ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0240","doi-asserted-by":"crossref","first-page":"e0130078","DOI":"10.1371\/journal.pone.0130078","article-title":"Methotrexate is a JAK\/STAT pathway inhibitor","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.abd.2020.05.006_bib0245","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000441250","article-title":"Efficacy and safety of methotrexate combined with low-to moderate-dose corticosteroids for severe Alopecia Areata","volume":"232","author":"Anuset","year":"2016","journal-title":"Dermatology."},{"key":"10.1016\/j.abd.2020.05.006_bib0250","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1590\/abd1806-4841.20142869","article-title":"Efficacy and safety of methotrexate in alopecia areata","volume":"89","author":"Hammerschmidt","year":"2014","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.06.064","article-title":"Methotrexate for alopecia areata: a systematic review and meta-analysis","volume":"80","author":"Phan","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0260","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.autrev.2014.08.027","article-title":"Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients","volume":"13","author":"Kivity","year":"2014","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.abd.2020.05.006_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2011.00839.x","article-title":"The use of methotrexate in dermatology: a review","volume":"53","author":"Shen","year":"2012","journal-title":"Australas J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0270","article-title":"Does daily folic acid supplementation reduce methotrexate efficacy?","volume":"23","author":"Cline","year":"2017","journal-title":"Dermatol Online J."},{"key":"10.1016\/j.abd.2020.05.006_bib0275","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2019.04.053","article-title":"Cyclosporine for moderate-to-severe alopecia areata: a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety","volume":"81","author":"Lai","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0280","doi-asserted-by":"crossref","first-page":"569","DOI":"10.5021\/ad.2016.28.5.569","article-title":"A Comparative study of oral cyclosporine and betamethasone minipulse therapy in the treatment of Alopecia Areata","volume":"28","author":"Jang","year":"2016","journal-title":"Ann Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0285","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1517\/14656566.2012.685160","article-title":"Treatment options for alopecia: an update, looking to the future","volume":"13","author":"Miteva","year":"2012","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.abd.2020.05.006_bib0290","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jaad.2015.12.055","article-title":"Treatment of recalcitrant adult alopecia areata universalis with oral azathioprine","volume":"74","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0295","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.15834","article-title":"Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata?","volume":"33","author":"Mascia","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2020.05.006_bib0300","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic Tlymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med."},{"key":"10.1016\/j.abd.2020.05.006_bib0305","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight."},{"key":"10.1016\/j.abd.2020.05.006_bib0310","doi-asserted-by":"crossref","first-page":"e13053","DOI":"10.1111\/dth.13053","article-title":"The role of Janus kinase inhibitors in the treatment of alopecia areata: a systematic review","volume":"32","author":"de Oliveira","year":"2019","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2020.05.006_bib0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0320","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight."},{"key":"10.1016\/j.abd.2020.05.006_bib0325","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An Open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type Alopecia Areata, Totalis, and Universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0330","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.15937","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis","volume":"34","author":"Guo","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2020.05.006_bib0335","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2020.05.006_bib0340","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jdcr.2016.01.005","article-title":"Hydroxychloroquine is ineffective in treatment of alopecia totalis and extensive alopecia areata: a case series of 8 patients","volume":"2","author":"Nissen","year":"2016","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.abd.2020.05.006_bib0345","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/pde.13451","article-title":"Alopecia areata treated with hydroxychloroquine: a retrospective study of nine pediatric cases","volume":"35","author":"Yun","year":"2018","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0350","first-page":"2","article-title":"Oral zinc sulphate in treatment of alopecia areata (double blind; crossover study)","volume":"3","author":"Sharquie","year":"2012","journal-title":"J Clin Exp Dermatol Res."},{"key":"10.1016\/j.abd.2020.05.006_bib0355","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2133.1981.tb15323.x","article-title":"Oral zinc sulphate in alopacia areata\u2014a double blind trial","volume":"104","author":"Ead","year":"1981","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0360","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaad.2006.10.980","article-title":"Is there a role for sulfasalazine in the treatment of alopecia areata?","volume":"57","author":"Bakar","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0365","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/ijt.ijt_14_18","article-title":"Mesalazine in the treatment of extensive alopecia areata: a new therapeutic option?","volume":"10","author":"Kiszewski","year":"2018","journal-title":"Int J Trichology."},{"key":"10.1016\/j.abd.2020.05.006_bib0370","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2014.11.006","article-title":"Treatment of alopecia areata with simvastatin\/ezetimibe","volume":"72","author":"Lattouf","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0375","doi-asserted-by":"crossref","first-page":"755","DOI":"10.5021\/ad.2017.29.6.755","article-title":"Simvastatin\/ezetimibe therapy for recalcitrant alopecia areata: an open prospective study of 14 patients","volume":"29","author":"Choi","year":"2017","journal-title":"Ann Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0380","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jaad.2015.09.071","article-title":"Alopecia areata (AA) and treatment with simvastatin\/ezetimibe: experience of 20 patients","volume":"74","author":"Loi","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0385","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jisp.2017.10.013","article-title":"Treatment of Alopecia Areata with Simvastatin\/Ezetimibe","volume":"19","author":"Cervantes","year":"2018","journal-title":"J Investig Dermatol Symp Proc."},{"key":"10.1016\/j.abd.2020.05.006_bib0390","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/archderm.1987.01660350088019","article-title":"Evaluation of oral minoxidil in the treatment of alopecia areata","volume":"123","author":"Fiedler-Weiss","year":"1987","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0395","article-title":"Combination tofacitinib and oral minoxidil treatment for severe alopecia areata","author":"Wambier","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0400","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10103-017-2412-6","article-title":"A review of monochromatic light devices for the treatment of alopecia areata","volume":"33","author":"Darwin","year":"2018","journal-title":"Lasers Med Sci."},{"key":"10.1016\/j.abd.2020.05.006_bib0405","first-page":"1","article-title":"Meta-analysis of 308-nm excimer laser therapy for alopecia areata","author":"Gupta","year":"2019","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.abd.2020.05.006_bib0410","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14764172.2016.1248440","article-title":"A review on laser and light-based therapies for alopecia areata","volume":"19","author":"Mlacker","year":"2017","journal-title":"J Cosmet Laser Ther."},{"key":"10.1016\/j.abd.2020.05.006_bib0415","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/ijd.13572","article-title":"Escalating dosimetry of UVA-1 in the treatment of alopecia areata","volume":"56","author":"Herz-Ruelas","year":"2017","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0420","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2133.1995.tb02628.x","article-title":"Dapsone versus topical immunotherapy in alopecia areata","volume":"133","author":"van Baar","year":"1995","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0425","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2133.1981.tb08179.x","article-title":"Unsuccessful treatment of alopecia areata with dapsone","volume":"104","author":"Friedmann","year":"1981","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0430","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/DSS.0000000000001965","article-title":"Platelet-rich plasma and its utilities in alopecia: a systematic review","volume":"46","author":"Hesseler","year":"2020","journal-title":"Dermatol Surg."},{"key":"10.1016\/j.abd.2020.05.006_bib0435","article-title":"An overview of the biology of platelet-rich plasma and microneedling as potential treatments for alopecia areata","volume":"19","author":"Strazzulla","year":"2018","journal-title":"J Investg Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0440","doi-asserted-by":"crossref","first-page":"505","DOI":"10.5021\/ad.2018.30.4.505","article-title":"Role of hair prostheses (wigs) in patients with severe alopecia areata","volume":"30","author":"Park","year":"2018","journal-title":"Ann Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0445","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/1346-8138.12040","article-title":"Psychosocial impact of wigs or hairpieces on perceived quality of life level in female patients with alopecia areata","volume":"40","author":"Inui","year":"2013","journal-title":"J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0450","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","article-title":"Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0455","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/archdermatol.2012.1622","article-title":"The safety and efficacy of diphencyprone for the treatment of alopecia areata in children","volume":"148","author":"Salsberg","year":"2012","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0460","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jdv.13896","article-title":"Beard alopecia areata: a multicentre review of 55 patients","volume":"31","author":"Saceda-Corralo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2020.05.006_bib0465","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/bjd.12863","article-title":"How effective is intralesional injection of triamcinolone acetonide compared with topical treatments in inducing and maintaining hair growth in patients with alopecia areata? A critically appraised topic","volume":"170","author":"Kassim","year":"2014","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2020.05.006_bib0470","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/13543784.2017.1303480","article-title":"Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia","volume":"26","author":"Barr\u00f3n-Hern\u00e1ndez","year":"2017","journal-title":"Expert Opin Investig Drugs."},{"key":"10.1016\/j.abd.2020.05.006_bib0475","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0974-7753.77511","article-title":"Bimatoprost in the treatment of eyelash universalis alopecia areata","volume":"2","author":"Vila","year":"2010","journal-title":"Int J Trichology."},{"key":"10.1016\/j.abd.2020.05.006_bib0480","first-page":"419","article-title":"An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects","volume":"10","author":"Borchert","year":"2016","journal-title":"Clin Ophthalmol."},{"key":"10.1016\/j.abd.2020.05.006_bib0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.10.048","article-title":"Objective outcome measures: collecting meaningful data on alopecia areata","volume":"79","author":"Olsen","year":"2018","journal-title":"J Am Acad Dermatol."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036505962030235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036505962030235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:40:27Z","timestamp":1759794027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036505962030235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":97,"alternative-id":["S036505962030235X"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2020.05.006","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus on the treatment of alopecia areata \u2013 Brazilian Society of Dermatology","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2020.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}